Online citations, reference lists, and bibliographies.
← Back to Search

Phase I Study Of Infusional Paclitaxel In Combination With The P-glycoprotein Antagonist PSC 833.

I. Chico, M. Kang, R. Bergan, J. Abraham, S. Bakke, B. Meadows, A. Rutt, R. Robey, P. Choyke, M. Merino, B. Goldspiel, T. Smith, S. Steinberg, W. Figg, T. Fojo, S. Bates
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
PURPOSE PSC 833 (valspodar) is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance. We conducted a phase I study of a 7-day oral administration of PSC 833 in combination with paclitaxel, administered as a 96-hour continuous infusion. PATIENTS AND METHODS Fifty patients with advanced cancer were enrolled onto the trial. PSC 833 was administered orally for 7 days, beginning 72 hours before the start of the paclitaxel infusion. Paclitaxel dose reductions were planned because of the pharmacokinetic interactions known to occur with PSC 833. RESULTS In combination with PSC 833, maximum-tolerated doses were defined as paclitaxel 13.1 mg/m(2)/d continuous intravenous infusion (CIVI) for 4 days without filgrastim, and paclitaxel 17.5 mg/m(2)/d CIVI for 4 days with filgrastim support. Dose-limiting toxicity for the combination was neutropenia. Statistical analysis of cohorts revealed similar mean steady-state concentrations (C(pss)) and areas under the concentration-versus-time curve (AUCs) when patients received paclitaxel doses of 13.1 or 17.5 mg/m(2)/d for 4 days with PSC 833, as when they received a paclitaxel dose of 35 mg/m(2)/d for 4 days without PSC 833. However, the effect of PSC 833 on paclitaxel pharmacokinetics varied greatly among individual patients, although a surrogate assay using CD56+ cells suggested inhibition of Pgp was complete or nearly complete at low concentrations of PSC 833. Responses occurred in three of four patients with non-small-cell lung cancer, and clinical benefit occurred in five of 10 patients with ovarian carcinoma. CONCLUSION PSC 833 in combination with paclitaxel can be administered safely to patients provided the paclitaxel dose is reduced to compensate for the pharmacokinetic interaction. Surrogate studies with CD56+ cells indicate that the maximum-tolerated dose for PSC 833 gives serum levels much higher than those required to block Pgp. The variability in paclitaxel pharmacokinetics, despite complete inhibition of Pgp in the surrogate assay, suggests that other mechanisms, most likely related to P450, contribute to the pharmacokinetic interaction. Future development of combinations such as this should include strategies to predict pharmacokinetics of the chemotherapeutic agent. This in turn will facilitate dosing to achieve comparable CPss and AUCs.
This paper references
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.
T. Tsuruo (1981)
P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines
G. M. Lai (1991)
SDZ PSC 833, A non‐immunosuppressive cyclosporine: Its potency in overcoming P‐glycoprotein‐mediated multidrug resistance of murine leukemia
R. Keller (1992)
Drug metabolism by cytochromes P450 in the liver and small bowel.
P. Watkins (1992)
Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.
D. Drach (1992)
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.
A. Yahanda (1992)
P-glycoprotein expression and function in circulating blood cells from normal volunteers.
W. Klimecki (1994)
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
K. Kivistö (1995)
Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
A. Schinkel (1995)
Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.
A. Chang (1995)
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
V. Wacher (1995)
The erythromycin breath test predicts the clearance of midazolam
K. Lown (1995)
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
P. Watkins (1995)
Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
P. Sonneveld (1996)
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
D. Boote (1996)
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
A. Seidman (1996)
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
J. van Asperen (1996)
Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
S. M. Witherspoon (1996)
Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
B. Samuels (1997)
Multidrug resistance: molecular mechanisms and clinical relevance
V. Ling (1997)
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
G. Giaccone (1997)
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
S. Kornblau (1997)
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
M. Huizing (1997)
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
E. Rowinsky (1998)
PSC833: initial clinical results in refractory ovarian cancer patients.
A. Fields (1998)
Pharmacokinetics of Dexamethasone and Valspodar, a P‐glycoprotein (mdr1) Modulator: Implications for Coadministration
J. Kovarik (1998)
Future perspectives for the development of P-glycoprotein modulators.
V. Sandor (1998)
Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833
R. Robey (1999)
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
R. Advani (1999)
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
P. Fracasso (2000)

This paper is referenced by
Therapeutic strategies to overcome taxane resistance in cancer.
Tuyelee Das (2021)
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
L. Mosca (2021)
P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients.
T. Stage (2020)
7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer.
Enxia Zhang (2019)
Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance
Xingping Quan (2019)
Coadministration of antiepileptic drugs and P-glycoprotein inhibitors of flavonoid-type
A. Ferreira (2018)
Evaluating local skin heating as an early detection method for small-fiber neuropathy in women with breast cancer receiving paclitaxel (Taxol®)
N. Zanville (2018)
Sex-specific modulation of drug bioavailability with pharmaceutical excipients
Y. Mai (2018)
Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Ilaria Genovese (2017)
The therapeutic potential of targeting ABC transporters to combat multi-drug resistance
Piyush Bugde (2017)
Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review
T. Stage (2017)
Xunan Shen (2017)
Targeting Chemotherapy Resistance in Glioblastoma Through Modulation of ABC Transporters
A. Tivnan (2016)
The Role of Transporters in Drug Delivery and Excretion
M. Morris (2016)
Biodegradable mixed MPEG-SS-2SA/TPGS micelles for triggered intracellular release of paclitaxel and reversing multidrug resistance
K. Dong (2016)
P‐Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer
K. Mealey (2015)
The role of ABC transporters in ovarian cancer progression and chemoresistance.
M. Ween (2015)
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.
Renata Silva (2015)
Reversal of P-glycoprotein-medicated multidrug resistance by LBM-A5 in vitro and a study of its pharmacokinetics in vivo.
Tianxiao Zhao (2015)
ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition
P. Massey (2014)
The Strong In Vivo Anti-Tumor Effect of the UIC2 Monoclonal Antibody Is the Combined Result of Pgp Inhibition and Antibody Dependent Cell-Mediated Cytotoxicity
Gábor Szalóki (2014)
Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers.
W. Hong (2013)
Ramola Sane (2012)
Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
E. Bajelan (2012)
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
M. Yu (2012)
Cancer Therapy: Clinical A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
R. Kelly (2011)
A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
R. Kelly (2010)
Phase I study of valspodar (PSC‐833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group
M. O'Brien (2010)
Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat.
Z. Binkhathlan (2010)
Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat
Z. Binkhathlan (2010)
Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.
N. Colabufo (2010)
Introduction to Drug Transporters
Louis Leung (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar